NCT03262779View on ClinicalTrials.gov

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIOLOGICAL

combination nivolumab and ipilimumab

Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.

Trial Locations (1)

06510

Yale Cancer Center, New Haven

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Yale University

OTHER

NCT03262779 - Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter